Boston files PMA (premarket approval application) for Express2 stent:
This article was originally published in Clinica
Boston Scientific has filed a premarket approval application with the US FDA for its Express2 stent system, which the firm plans to use as the platform for its drug-eluting stent programme. The balloon-expandable Express2 stent system combines a flexible tip with a long, low profile for easier tracking and a hydrophilic coating that is designed to reduce friction, said the Natick, Massachusetts firm. Boston expects to launch the product in the US in May, and in other markets in September this year.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.